Equities
  • Price (EUR)8.43
  • Today's Change0.134 / 1.61%
  • Shares traded3.00
  • 1 Year change+33.01%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Novavax Inc had revenues fall -50.36% from 1.98bn to 983.71m, though the company grew net income from a loss of 657.94m to a smaller loss of 545.06m.
Gross margin63.67%
Net profit margin-29.80%
Operating margin-29.67%
Return on assets-16.80%
Return on equity--
Return on investment-78.53%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Novavax Inc fell by 765.04m. Cash Flow from Financing totalled 4.47m or 0.45% of revenues. In addition the company used 713.97m for operations while cash used for investing totalled 58.81m.
Cash flow per share-1.87
Price/Cash flow per share--
Book value per share-2.70
Tangible book value per share-3.47
More ▼

Balance sheet in USDView more

Novavax Inc uses little or no debt in its capital structure.
Current ratio1.04
Quick ratio1.03
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.